Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: US To Begin Mass Vaccinations After Pfizer’s Historic Emergency Authorization

Plus: India To Examine Healthcare Access

Executive Summary

The first vaccinations are due to begin in the US, with the government extending its agreement with Moderna to bolster its vaccines supplies.

You may also be interested in...



Will Moderna-NIH Patent Dispute Change Government-Industry Collaborations?

US government may add provisions to future agreements to ensure its inventorship rights and make terms more favorable to the public. Lawyers say it will be difficult for Moderna to exclude NIH as co-inventor. But NIH lost a similar battle over AZT patents.

How COVID-19 Defined 2020 For Biopharma

Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.

Coronavirus Update: Moderna Snags Vaccine EUA

The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel